Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
192 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Major Depressive Disorder - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Major Depressive Disorder - Pipeline Review, H2 2014', provides an overview of the Major Depressive Disorder's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Major Depressive Disorder and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Major Depressive Disorder pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Major Depressive Disorder Overview 9 Therapeutics Development 10 Pipeline Products for Major Depressive Disorder - Overview 10 Pipeline Products for Major Depressive Disorder - Comparative Analysis 11 Major Depressive Disorder - Therapeutics under Development by Companies 12 Major Depressive Disorder - Therapeutics under Investigation by Universities/Institutes 16 Major Depressive Disorder - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Major Depressive Disorder - Products under Development by Companies 21 Major Depressive Disorder - Products under Investigation by Universities/Institutes 24 Major Depressive Disorder - Companies Involved in Therapeutics Development 25 Johnson & Johnson 25 F. Hoffmann-La Roche Ltd. 26 Allergan, Inc. 27 Eli Lilly and Company 28 GlaxoSmithKline plc 29 Alkermes Plc 30 Sumitomo Dainippon Pharma Co., Ltd. 31 Neurocrine Biosciences, Inc. 32 Richter Gedeon Nyrt. 33 H. Lundbeck A/S 34 OPKO Health, Inc. 35 Neuralstem, Inc. 36 Avanir Pharmaceuticals, Inc. 37 Suven Life Sciences Ltd. 38 e-Therapeutics plc 39 Intas Pharmaceuticals Ltd. 40 Angelini Group 41 Trevena, Inc. 42 Azevan Pharmaceuticals, Inc. 43 Dart NeuroScience LLC 44 Intra-Cellular Therapies, Inc. 45 Otsuka Holdings Co., Ltd. 46 Reviva Pharmaceuticals Inc. 47 Luye Pharma Group Ltd. 48 Naurex, Inc. 49 NeurOp Corporation 50 Edgemont Pharmaceuticals, LLC 51 Methylation Sciences Inc. 52 Sunovion Pharmaceuticals Inc. 53 BioCrea GmbH 54 Lead Discovery Center GmbH 55 BRAINco Biopharma, S.L. 56 Bionure Farma, S.L. 57 Cerecor Inc. 58 SK Biopharmaceuticals Co., Ltd. 59 nLife Therapeutics, S.L. 60 Saniona AB 61 Major Depressive Disorder - Therapeutics Assessment 62 Assessment by Monotherapy Products 62 Assessment by Combination Products 63 Assessment by Target 64 Assessment by Mechanism of Action 68 Assessment by Route of Administration 72 Assessment by Molecule Type 74 Drug Profiles 76 vortioxetine hydrobromide - Drug Profile 76 lurasidone hydrochloride - Drug Profile 78 brexpiprazole - Drug Profile 80 cariprazine - Drug Profile 82 (samidorphan + buprenorphine hydrochloride) - Drug Profile 84 bupropion hydrochloride ER - Drug Profile 85 INASTR-001 - Drug Profile 86 trazodone hydrochloride - Drug Profile 87 (aripiprazole + sertraline) - Drug Profile 88 amitifadine - Drug Profile 89 edivoxetine - Drug Profile 91 verucerfont - Drug Profile 93 decoglurant - Drug Profile 95 SCH-900978 - Drug Profile 97 tramadol hydrochloride - Drug Profile 98 basimglurant - Drug Profile 100 onabotulinumtoxinA - Drug Profile 102 GLYX-13 - Drug Profile 104 CERC-301 - Drug Profile 106 LY-2940094 - Drug Profile 107 HT-2157 - Drug Profile 108 AVP-786 - Drug Profile 109 esketamine - Drug Profile 110 NRX-1074 - Drug Profile 111 MSI-195 - Drug Profile 112 tedatioxetine - Drug Profile 113 SRX-246 - Drug Profile 115 ITI-007 - Drug Profile 117 AN-788 - Drug Profile 119 SKL-DEP - Drug Profile 120 SEP-363856 - Drug Profile 121 LY-03005 - Drug Profile 122 NSI-189 - Drug Profile 123 NRX-1050 - Drug Profile 124 SUVN-911 - Drug Profile 125 Small Molecules to Agonize Delta Opioid Receptor for CNS Disorders - Drug Profile 126 Small Molecules to Antagonize NR2B for Major Depression - Drug Profile 127 NLF-NEU - Drug Profile 128 Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder - Drug Profile 129 Small Molecules to Target BRC02 for Major Depressive Disorder - Drug Profile 130 Small Molecules Targeting SLC6A15 for Major Depressive Disorder - Drug Profile 131 BN-201 - Drug Profile 132 Small Molecules to Inhibit NMDA Receptor and CHRNA7 for CNS - Drug Profile 133 Small Molecule Targeting FKBP51 for Major Depressive Disorder - Drug Profile 134 RP-5063 - Drug Profile 135 EDG-005 - Drug Profile 136 Major Depressive Disorder - Recent Pipeline Updates 137 Major Depressive Disorder - Dormant Projects 177 Major Depressive Disorder - Discontinued Products 179 Major Depressive Disorder - Product Development Milestones 180 Featured News & Press Releases 180 Appendix 188 Methodology 188 Coverage 188 Secondary Research 188 Primary Research 188 Expert Panel Validation 188 Contact Us 189 Disclaimer 189
List of Tables Number of Products under Development for Major Depressive Disorder, H2 2014 13 Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Development by Companies, H2 2014 (Contd..1) 17 Number of Products under Development by Companies, H2 2014 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H2 2014 19 Comparative Analysis by Late Stage Development, H2 2014 20 Comparative Analysis by Clinical Stage Development, H2 2014 21 Comparative Analysis by Early Stage Development, H2 2014 22 Comparative Analysis by Unknown Stage Development, H2 2014 23 Products under Development by Companies, H2 2014 24 Products under Development by Companies, H2 2014 (Contd..1) 25 Products under Development by Companies, H2 2014 (Contd..2) 26 Products under Investigation by Universities/Institutes, H2 2014 27 Major Depressive Disorder - Pipeline by Johnson & Johnson, H2 2014 28 Major Depressive Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 29 Major Depressive Disorder - Pipeline by Allergan, Inc., H2 2014 30 Major Depressive Disorder - Pipeline by Eli Lilly and Company, H2 2014 31 Major Depressive Disorder - Pipeline by GlaxoSmithKline plc, H2 2014 32 Major Depressive Disorder - Pipeline by Alkermes Plc, H2 2014 33 Major Depressive Disorder - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 34 Major Depressive Disorder - Pipeline by Neurocrine Biosciences, Inc., H2 2014 35 Major Depressive Disorder - Pipeline by Richter Gedeon Nyrt., H2 2014 36 Major Depressive Disorder - Pipeline by H. Lundbeck A/S, H2 2014 37 Major Depressive Disorder - Pipeline by OPKO Health, Inc., H2 2014 38 Major Depressive Disorder - Pipeline by Neuralstem, Inc., H2 2014 39 Major Depressive Disorder - Pipeline by Avanir Pharmaceuticals, Inc., H2 2014 40 Major Depressive Disorder - Pipeline by Suven Life Sciences Ltd., H2 2014 41 Major Depressive Disorder - Pipeline by e-Therapeutics plc, H2 2014 42 Major Depressive Disorder - Pipeline by Intas Pharmaceuticals Ltd., H2 2014 43 Major Depressive Disorder - Pipeline by Angelini Group, H2 2014 44 Major Depressive Disorder - Pipeline by Trevena, Inc., H2 2014 45 Major Depressive Disorder - Pipeline by Azevan Pharmaceuticals, Inc., H2 2014 46 Major Depressive Disorder - Pipeline by Dart NeuroScience LLC, H2 2014 47 Major Depressive Disorder - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 48 Major Depressive Disorder - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 49 Major Depressive Disorder - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 50 Major Depressive Disorder - Pipeline by Luye Pharma Group Ltd., H2 2014 51 Major Depressive Disorder - Pipeline by Naurex, Inc., H2 2014 52 Major Depressive Disorder - Pipeline by NeurOp Corporation, H2 2014 53 Major Depressive Disorder - Pipeline by Edgemont Pharmaceuticals, LLC, H2 2014 54 Major Depressive Disorder - Pipeline by Methylation Sciences Inc., H2 2014 55 Major Depressive Disorder - Pipeline by Sunovion Pharmaceuticals Inc., H2 2014 56 Major Depressive Disorder - Pipeline by BioCrea GmbH, H2 2014 57 Major Depressive Disorder - Pipeline by Lead Discovery Center GmbH, H2 2014 58 Major Depressive Disorder - Pipeline by BRAINco Biopharma, S.L., H2 2014 59 Major Depressive Disorder - Pipeline by Bionure Farma, S.L., H2 2014 60 Major Depressive Disorder - Pipeline by Cerecor Inc., H2 2014 61 Major Depressive Disorder - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 62 Major Depressive Disorder - Pipeline by nLife Therapeutics, S.L., H2 2014 63 Major Depressive Disorder - Pipeline by Saniona AB, H2 2014 64 Assessment by Monotherapy Products, H2 2014 65 Assessment by Combination Products, H2 2014 66 Number of Products by Stage and Target, H2 2014 69 Number of Products by Stage and Mechanism of Action, H2 2014 73 Number of Products by Stage and Route of Administration, H2 2014 76 Number of Products by Stage and Molecule Type, H2 2014 78 Major Depressive Disorder Therapeutics - Recent Pipeline Updates, H2 2014 140 Major Depressive Disorder - Dormant Projects, H2 2014 180 Major Depressive Disorder - Discontinued Products, H2 2014 182
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
